ImmunoPrecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth
Victoria, British Columbia, Canada, May 24, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management and board members, it has appointed Jennifer L. Bath, the Chief Executive Officer and President of ImmunoPrecise, as a member of its board of directors.
“Under Jennifer’s leadership, ImmunoPrecise has evolved into the first full-service discovery antibody CRO in North America and Europe,” comments James Kuo, Chairman of ImmunoPrecise. “Over the last three months, Jennifer oversaw our immediately accretive acquisition of ModiQuest, the addition of our new facility that provides B-cell sorting capabilities and our focus on antibody discovery for therapeutic antibodies. We are extremely supportive of Jennifer’s vision to create a global single source CRO from inception of the target to clinical trials.”
Also as part of the expansion of its senior leadership team to achieve global growth objectives, the company is pleased to announce two new appointments: Charles (Chip) Wheelock as the global Chief Technology Officer and Kari Graber as the Director of Global Client Services and Project Management.
Chip Wheelock, Chief Technology Officer: Mr. Wheelock brings a diverse background to IPA, he has held leadership positions within the software development and services industries over the past 25 years encompassing global ERP deployments, cloud transformations and building strategic line of business applications. Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a Senior Global Technical Account Manager, where he drove both strategic and technical initiatives for many large organizations. Mr. Wheelock holds a Bachelor’s degree from the University of Kansas along with several industry and project management certifications.
Kari Graber, Director of Global Project Management: Kari has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC where she held a client relations management role for their antibody services platform. Kari holds a Bachelor of Science in Food Science & Technology with a Minor in Microbiology from North Dakota State University.
“The expansion of our senior leadership in the areas of information technology, client services and project management positions IPA to further its growth as a single provider of integrated antibody discovery for therapeutic drug discovery,” said Jennifer L. Bath, President and CEO of IPA. “We believe these positions further equip IPA to fully integrate each of our business units located in North America and Europe to provide a seamless value chain to our clients as IPA expands globally.”
At the same time as the Company restructures to align each of North American and European business units for global growth, IPA wishes to acknowledge the contribution of Reg Beniac, former Chief Operating Officer (“COO”) who has moved on to other opportunities. Mr. Beniac stepped in as the COO and steered the Company through a transformational time. He played a central role in moving IPA from a private to a public company model, was a key member of the acquisition team, returned the Victoria business to operational profitability, in addition to leading credibly during Executive level staffing changes.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state of the art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care and in association with U-Protein Express B.V. its subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands.
The services offered to customers include the development of wild-type and humanized mouse and rat monoclonal antibodies and recombinant rabbit monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically-based assays, recombinant protein manufacturing, and advanced solutions to challenges faced by clients in antibody-related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
ImmunoPrecise employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO and President
3204-4464 Markham Street
Victoria, BC V8Z 7X8
For investor relations please contact:
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.